top of page
The Professional Network for Healthcare Experts
Biogen Advances Tau-Targeting Alzheimer’s Drug Diranersen Despite Phase II Dose Uncertainty
Detailed CELIA trial results show Biogen and Ionis’ diranersen slowed cognitive decline in early Alzheimer’s disease, but questions remain over why the lowest dose delivered the strongest clinical benefit.
nuaxia
Jul 154 min read
Lilly Adds Another Alzheimer’s Bet With $1bn Push Into Amyloid Modulation
Eli Lilly has signed a licensing deal worth up to $1bn with Swedish biotech AlzeCure Pharma for ACD680, a preclinical Alzheimer’s programme targeting amyloid-beta production via gamma-secretase modulation.
nuaxia
Jun 112 min read
1st Annual Dementia & Alzheimer’s Education Conference Unites Caregivers and Clinicians
CaringKind hosted its first Dementia & Alzheimer’s Education Conference at the New York Academy of Medicine, bringing together caregivers, clinicians, researchers, and people living with dementia.
nuaxia
Apr 11 min read
bottom of page